Drug Profile
8H9 bispecific antibody - Y-mAbs Therapeutics
Alternative Names: Hu8H9-BsAb (B7-H3xCD3)Latest Information Update: 09 Sep 2016
Price :
$50
*
At a glance
- Originator Y-mAbs Therapeutics
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action CD antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 09 Sep 2016 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
- 16 Jun 2016 Preclinical trials in Solid tumours in USA (unspecified route) (Y-mAbs Therapeutics pipeline, June 2016)